Programming biologic medicines to act only where they are needed - and nowhere else.
Inside a lab on the edge of Boston, a team of 73 people is teaching medicine a skill it has somehow never had: a sense of place. Their molecules carry two instructions - find the disease, then act only there. Everywhere else, stay quiet.
Ampersand Biomedicines does not look like a company built on a punctuation mark, but it is. The ampersand joins two things. So does every drug it designs: a part that locates, and a part that works. The whole bet sits in that little symbol - the idea that the second instruction is useless without the first.
Most side effects are just medicine showing up to the wrong address.
The premise, in one sentenceThe trouble with a potent drug is that it is potent everywhere. Swallow a pill, infuse a biologic, and the molecule floods the whole body, hunting its target in the diseased tissue and finding the same target in healthy tissue too. The result is the familiar bargain of modern medicine: turn the dose up for effect, and the side effects climb with it. Turn it down to be safe, and you may lose the benefit.
This is the narrow gap drug developers call the therapeutic window, and for decades it has set the ceiling on what biologics can do. Ampersand's founders looked at that ceiling and asked a question that sounds obvious until you try to answer it: what if the medicine only switched on once it arrived?
Turn the dose up for effect, turn it down for safety. Ampersand refuses to accept that trade.
The window, and the wagerThe company was incubated in 2020 inside Flagship Pioneering, the Cambridge venture firm best known for founding Moderna. Co-founder Noubar Afeyan framed the thesis bluntly: "Most existing medicines affect cells not just at the site of disease but throughout the body. What if we could direct medicines in a programmable way?"
It is the kind of question that is easy to ask and expensive to answer. The founding team - Afeyan, Avak Kahvejian, Raffi Afeyan, Yann Echelard, Charlotte Nicod and Nick Plugis - was assembled around the conviction that biology could be addressed, not just targeted. The distinction matters. Targeting finds a molecule. Addressing finds a place. Flagship put $50 million behind the difference and, in 2023, unveiled the company to the public. Jason Gardner took the chief executive's chair.
Targeting finds a molecule. Addressing finds a place. Ampersand is built on that one-word difference.
Avak Kahvejian, Co-FounderFounded inside Flagship Pioneering as an attempt to give biologic medicines a programmable sense of location.
Flagship publicly launches Ampersand with a $50 million commitment, introducing the AND Platform and AND-Body Therapeutics.
Discovery collaborations form with Pfizer and Pioneering Medicines on metabolic pathways, and with Genethon on AAV gene-therapy vectors.
A $65 million round, with Eli Lilly joining as a strategic investor. Two lead programs in immuno-inflammation and immuno-oncology are slated for IND-enabling studies; a second obesity partnership is announced.
The platform's name is also its method. The AND Platform runs multi-omics analysis to build what the company calls an Address Map - a computational atlas of which molecular markers reliably point to a specific organ, cell type or disease. Find a good address, and you can design a molecule to anchor there.
The drugs themselves are AND-Body Therapeutics: modular, multi-specific biologics that pair a localizing element with an actuator. The localizer drops the molecule at the right place. The actuator stays dormant until it arrives, then conditionally switches on the therapeutic biology. The body never gets the full dose - only the disease does.
Computational engine that reads multi-omics data to identify ideal "addresses" for drug localization across organs, cells and diseases.
Modular biologics that combine a localizer and an actuator - they anchor at disease and conditionally activate only there.
The proprietary atlas of localizing targets that tells the platform where, precisely, a medicine should report for duty.
Caption: yes, the whole thing is essentially a very expensive postal system for molecules. Stamps not included.
A platform is a hypothesis until someone with a checkbook agrees. In March 2025, Ampersand closed a $65 million Series B led by Flagship - and, more tellingly, with Eli Lilly joining as a strategic investor. Pharma giants do not write checks into platforms they expect to fail. Pfizer and Genethon had already signed on as discovery partners, betting the localization idea works across metabolic disease and gene therapy alike.
Pharma giants do not write checks into platforms they expect to fail.
On the Lilly signalAmpersand is not trying to make an existing drug slightly safer. It is trying to make a new kind of drug - what Kahvejian calls "a fundamentally novel way to program biologics." The lead programs aim at immuno-inflammation and immuno-oncology, two fields where powerful drugs are routinely held back by what they do to the wrong tissue. A second front, obesity, runs through the Pfizer and Pioneering Medicines partnerships.
The wager is that one platform can aim at many diseases at once, because the problem it solves - getting a medicine to the right place and keeping it switched off everywhere else - is shared by nearly all of them.
We've unlocked a fundamentally novel way to program biologics, ushering in a new era of smarter medicines.
Avak Kahvejian, Co-FounderNone of this is approved yet. The lead programs are still walking toward the clinic, and biology has a long history of humbling clever ideas. Ampersand is, for now, a very well-funded promise.
But the promise is a serious one. Back in that Boston lab, the molecules are still learning their addresses. If they learn them well, the old bargain - effect versus safety, dose up versus dose down - stops being the ceiling it has always been. A drug that knows where it is could do its job and then, politely, stay out of everyone else's. The ampersand was right all along: it was never about the medicine alone. It was about the medicine, and the place.